Advertisement

Cancer of Other Origin

  • Ben Davidson
Chapter

Abstract

The peritoneal, pleural, and pericardial cavities may be the site of metastasis from practically any malignant tumor, including carcinomas, sarcomas, melanoma, hematological tumors, and pediatric cancers other than the aforementioned entities. Among carcinomas, which outnumber all other entities combined, lung, breast, ovarian, and gastrointestinal primaries are the most common ones. The first three entities are discussed elsewhere in this book. The majority of research focusing on other cancers has been directed at metastases from the gastrointestinal tract, focusing on metastasis-promoting molecules, predictive markers and prognostic markers, as well as targeted therapy. These are the main topics of this chapter. The few studies that have focused on other malignancies are additionally discussed.

Keywords

Tumor progression Gastrointestinal cancer Melanoma Diagnosis Cancer-associated molecules 

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.PubMedCrossRefGoogle Scholar
  2. 2.
    Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036.CrossRefPubMedGoogle Scholar
  3. 3.
    Chiaravalli M, Reni M, O'Reilly EM. Pancreatic ductal adenocarcinoma: state-of-the-art 2017 and new therapeutic strategies. Cancer Treat Rev. 2017;60:32–43.CrossRefPubMedGoogle Scholar
  4. 4.
    Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL, Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10–22.CrossRefPubMedGoogle Scholar
  5. 5.
    Das KK, Early D. Pancreatic cancer screening. Curr Treat Options Gastroenterol. 2017;15(4):562–75.  https://doi.org/10.1007/s11938-017-0149-8.CrossRefPubMedGoogle Scholar
  6. 6.
    Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73–85.CrossRefPubMedGoogle Scholar
  7. 7.
    Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.CrossRefPubMedGoogle Scholar
  9. 9.
    Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390(10110):2383–96.CrossRefPubMedGoogle Scholar
  10. 10.
    Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, Park JO, Park YS, Lim HY, Sohn TS, Noh JH, Heo JS, Park CK, Kim S, Kang WK. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007;18:886–91.CrossRefPubMedGoogle Scholar
  11. 11.
    Lello E, Furnes B, Edna TH. Short and long-term survival from gastric cancer. A population-based study from a county hospital during 25 years. Acta Oncol. 2007;46:308–15.CrossRefPubMedGoogle Scholar
  12. 12.
    Ikeda M, Okusaka T, Ueno H, Morizane C, Kojima Y, Iwasa S, Hagihara A. Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma. Jpn J Clin Oncol. 2008;38:675–82.CrossRefPubMedGoogle Scholar
  13. 13.
    Carr BI, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatol Int. 2009;4:396–405.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ozyurtkan MO, Balci AE, Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion. Eur J Intern Med. 2010;21:30–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Maeda H, Kobayashi M, Sakamoto J. Evaluation and treatment of malignant ascites secondary to gastric cancer. World J Gastroenterol. 2015;21:10936–47.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    DeWitt J, Yu M, Al-Haddad MA, Sherman S, McHenry L, Leblanc JK. Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA. Gastrointest Endosc. 2010;71:260–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Zervos EE, Osborne D, Boe BA, Luzardo G, Goldin SB, Rosemurgy AS. Prognostic significance of new onset ascites in patients with pancreatic cancer. World J Surg Oncol. 2006;4:16.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Nakata B, Nishino H, Ogawa Y, Yokomatsu H, Kawasaki F, Kosaka K, Wada T, Suto R, Montani A, Hirakawa K. Prognostic predictive value of endoscopic ultrasound findings for invasive ductal carcinomas of pancreatic head. Pancreas. 2005;30:200–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Hicks AM, Chou J, Capanu M, Lowery MA, Yu KH, O'Reilly EM. Pancreas adenocarcinoma: ascites, clinical manifestations, and management implications. Clin Colorectal Cancer. 2016;15(4):360–8.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Shukuya T, Yasui H, Boku N, Onozawa Y, Fukutomi A, Yamazaki K, Taku K, Kojima T, Machida N. Weekly paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study. Jpn J Clin Oncol. 2010;40:1135–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Yonemori K, Okusaka T, Ueno H, Morizane C, Takesako Y, Ikeda M. FP therapy for controlling malignant ascites in advanced pancreatic cancer patients. Hepato-Gastroenterology. 2007;54:2383–6.PubMedGoogle Scholar
  22. 22.
    Warshaw AL. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg. 1991;161:26–9; Discussion 29–30.CrossRefGoogle Scholar
  23. 23.
    Cascinu S, Del Ferro E, Barbanti I, Ligi M, Fedeli A, Catalano G. Tumor markers in the diagnosis of malignant serous effusions. Am J Clin Oncol. 1997;20:247–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Yu CJ, Shew JY, Liaw YS, Kuo SH, Luh KT, Yang PC. Application of mucin quantitative competitive reverse transcription polymerase chain reaction in assisting the diagnosis of malignant pleural effusion. Am J Respir Crit Care Med. 2001;164:1312–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Yamashita K, Kuba T, Shinoda H, Takahashi E, Okayasu I. Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination. Am J Clin Pathol. 1998;109:704–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Li CP, Huang TS, Chao Y, Chang FY, Whang-Peng J, Lee SD. Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies. World J Gastroenterol. 2004;10:2468–71.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Tangkijvanich P, Tresukosol D, Sampatanukul P, Sakdikul S, Voravud N, Mahachai V, Mutirangura A. Telomerase assay for differentiating between malignancy-related and nonmalignant ascites. Clin Cancer Res. 1999;5:2470–5.PubMedGoogle Scholar
  28. 28.
    Wong J, Schulman A, Kelly K, Zamarin D, Palese P, Fong Y. Detection of free peritoneal cancer cells in gastric cancer using cancer-specific Newcastle disease virus. J Gastrointest Surg. 2010;14:7–14.CrossRefPubMedGoogle Scholar
  29. 29.
    Cornfield DB, Gheith SM. Flow cytometric quantitation of natural killer cells and T lymphocytes expressing T-cell receptors alpha/beta and gamma/delta is not helpful in distinguishing benign from malignant body cavity effusions. Cytometry B Clin Cytom. 2009;76:213–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Wang F, Yang L, Gao Q, Huang L, Wang L, Wang J, Wang S, Zhang B, Zhang Y. CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion. Cancer Immunol Immunother. 2015;64:965–76.CrossRefPubMedGoogle Scholar
  31. 31.
    Scherpereel A, Grigoriu BD, Noppen M, Gey T, Chahine B, Baldacci S, Trauet J, Copin MC, Dessaint JP, Porte H, Labalette M. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid. BMC Cancer. 2013;13:324.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, Al-Ahmadie H, Alves V, Xiao SY, Anders RA, Hart JA. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010;34:1147–54.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Villamil FG, Sorroche PB, Aziz HF, Lopez PM, Oyhamburu JM. Ascitic fluid alpha 1-antitrypsin. Dig Dis Sci. 1990;35:1105–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Lee CM, Changchien CS, Shyu WC, Liaw YF. Serum-ascites albumin concentration gradient and ascites fibronectin in the diagnosis of malignant ascites. Cancer. 1992;70:2057–60.CrossRefPubMedGoogle Scholar
  35. 35.
    Colli A, Cocciolo M, Riva C, Marcassoli L, Pirola M, Di Gregorio P, Buccino G. Ascitic fluid analysis in hepatocellular carcinoma. Cancer. 1993;72:677–82.CrossRefPubMedGoogle Scholar
  36. 36.
    Greco AV, Mingrone G, Gasbarrini G. Free fatty acid analysis in ascitic fluid improves diagnosis in malignant abdominal tumors. Clin Chim Acta. 1995;239:13–22.CrossRefPubMedGoogle Scholar
  37. 37.
    Stephen MR, Oien K, Ferrier RK, Burnett RA. Effusion cytology of hepatocellular carcinoma with in situ hybridisation for human albumin. J Clin Pathol. 1997;50:442–4.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Miédougé M, Salama G, Barange K, Vincent C, Vinel JP, Serre G. Evaluation of alpha-fetoprotein assay in ascitic fluid for the diagnosis of hepatocellular carcinoma. Clin Chim Acta. 1999;280:161–71.CrossRefPubMedGoogle Scholar
  39. 39.
    Castaldo G, Intrieri M, Calcagno G, Cimino L, Budillon G, Sacchetti L, Salvatore F. Ascitic pseudouridine discriminates between hepatocarcinoma-derived ascites and cirrhotic ascites. Clin Chem. 1996;42:1843–6.PubMedGoogle Scholar
  40. 40.
    Dong WG, Sun XM, Yu BP, Luo HS, Yu JP. Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol. 2003;9:2596–600.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999;6:373–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marmé D, Gastl G. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85:178–87.CrossRefPubMedGoogle Scholar
  43. 43.
    Tamai M, Tanimura H, Yamaue H, Iwahashi M, Tsunoda T, Tani M, Noguchi K, Mizobata S, Hotta T, Arii K, Terasawa H. Clinical significance of quantitative analysis of carcinoembryonic antigen assessed by flow cytometry in fresh human gastric cancer cells. Cancer Lett. 1995;90:111–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Jung M, Jeung HC, Lee SS, Park JY, Hong S, Lee SH, Noh SH, Chung HC, Rha SY. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. J Cancer Res Clin Oncol. 2010;136:517–26.CrossRefPubMedGoogle Scholar
  45. 45.
    Matsuura K, Kawanishi J, Fujii S, Imamura M, Hirano S, Takeichi M, Niitsu Y. Altered expression of E-cadherin in gastric cancer tissues and carcinomatous fluid. Br J Cancer. 1992;66:1122–30.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Koyama S, Maruyama T, Adachi S. Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis. J Cancer Res Clin Oncol. 1999;125:47–54.CrossRefPubMedGoogle Scholar
  47. 47.
    Kitayama J, Emoto S, Yamaguchi H, et al. Flow cytometric quantification of Intraperitoneal free tumor cells is a useful biomarker in gastric cancer patients with peritoneal metastasis. Ann Surg Oncol. 2015;22:2336–42.CrossRefPubMedGoogle Scholar
  48. 48.
    Sun XM, Dong WG, Yu BP, Luo HS, Yu JP. Detection of type IV collagenase activity in malignant ascites. World J Gastroenterol. 2003;9:2592–5.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Koyama S. Enhanced cell surface expression of matrix metalloproteinases and their inhibitors, and tumor-induced host response in progression of human gastric carcinoma. Dig Dis Sci. 2004;49:1621–30.CrossRefPubMedGoogle Scholar
  50. 50.
    Koyama S. Coordinate cell-surface expression of matrix metalloproteinases and their inhibitors on cancer-associated myofibroblasts from malignant ascites in patients with gastric carcinoma. J Cancer Res Clin Oncol. 2005;131:809–14.CrossRefPubMedGoogle Scholar
  51. 51.
    Koyama S, Koike N, Adachi S. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J Cancer Res Clin Oncol. 2001;127:20–6.CrossRefPubMedGoogle Scholar
  52. 52.
    Koyama S, Koike N, Adachi S. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol. 2002;128:73–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Koyama S. Differential expression of intracellular apoptotic signaling molecules in tumor and tumor-infiltrating lymphocytes during development of invasion and/or metastasis of gastric carcinoma. Dig Dis Sci. 2003;48:2290–300.CrossRefPubMedGoogle Scholar
  54. 54.
    Yoon SJ, Heo DS, Kang SH, Lee KH, Kim WS, Kim GP, Lee JA, Lee KS, Bang YJ, Kim NK. Natural killer cell activity depression in peripheral blood and ascites from gastric cancer patients with high TGF-beta 1 expression. Anticancer Res. 1998;18:1591–6.PubMedGoogle Scholar
  55. 55.
    Yuen MF, Norris S, Evans LW, Langley PG, Hughes RD. Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis. Scand J Gastroenterol. 2002;37:233–8.CrossRefPubMedGoogle Scholar
  56. 56.
    Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 2003;98:1089–99.CrossRefPubMedGoogle Scholar
  57. 57.
    Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, Xue J, Zhang FM, Ge HL, Xu D. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol. 2009;131:109–18.CrossRefPubMedGoogle Scholar
  58. 58.
    Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005;65:2457–64.CrossRefPubMedGoogle Scholar
  59. 59.
    Kono K, Ichihara F, Iizuka H, Sekikawa T, Matsumoto Y. Expression of signal transducing T-cell receptor zeta molecules after adoptive immunotherapy in patients with gastric and colon cancer. Int J Cancer. 1998;78:301–5.CrossRefPubMedGoogle Scholar
  60. 60.
    Hironaka K, Yamaguchi Y, Okita R, Okawaki M, Nagamine I. Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432. Anticancer Res. 2006;26:3701–7.PubMedGoogle Scholar
  61. 61.
    Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi Y, Yoshie O, Saiki I. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res. 2006;66:2181–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Misawa S, Horiike S, Taniwaki M, Tsuda S, Okuda T, Kashima K, Abe T, Sugihara H, Noriki S, Fukuda M. Chromosome abnormalities of gastric cancer detected in cancerous effusions. Jpn J Cancer Res. 1990;81:148–52.CrossRefPubMedGoogle Scholar
  63. 63.
    Trigo MI, San Martín MV, Novales MA, Maraví J. Cytogenetic studies of five gastric carcinomas metastatic to the pleura. Cancer Genet Cytogenet. 1994;75:145–6.CrossRefPubMedGoogle Scholar
  64. 64.
    Zojer N, Fiegl M, Müllauer L, Chott A, Roka S, Ackermann J, Raderer M, Kaufmann H, Reiner A, Huber H, Drach J. Chromosomal imbalances in primary and metastatic pancreatic carcinoma as detected by interphase cytogenetics: basic findings and clinical aspects. Br J Cancer. 1998;77:1337–42.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Sakakura C, Hagiwara A, Nakanishi M, Shimomura K, Takagi T, Yasuoka R, Fujita Y, Abe T, Ichikawa Y, Takahashi S, Ishikawa T, Nishizuka I, Morita T, Shimada H, Okazaki Y, Hayashizaki Y, Yamagishi H. Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites. Br J Cancer. 2002;87:1153–61.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Kosanam H, Makawita S, Judd B, Newman A, Diamandis EP. Mining the malignant ascites proteome for pancreatic cancer biomarkers. Proteomics. 2011;11:4551–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Tokuhisa M, Ichikawa Y, Kosaka N, Ochiya T, Yashiro M, Hirakawa K, Kosaka T, Makino H, Akiyama H, Kunisaki C, Endo I. Exosomal miRNAs from peritoneum lavage fluid as potential prognostic biomarkers of peritoneal metastasis in gastric cancer. PLoS One. 2015;10:e0130472.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Lim B, Kim C, Kim JH, Kwon WS, Lee WS, Kim JM, Park JY, Kim HS, Park KH, Kim TS, Park JL, Chung HC, Rha SY, Kim SY. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. Oncotarget. 2016;7:8055–66.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Savoia P, Quaglino P, Osella-Abate S, Comessatti A, Nardò T, Bernengo MG. Tyrosinase mRNA RT-PCR analysis as an additional diagnostic tool for the identification of melanoma cells in biological fluid samples other than blood: a preliminary report. Int J Biol Markers. 2005;20:11–7.CrossRefPubMedGoogle Scholar
  70. 70.
    Pirker C, Holzmann K, Spiegl-Kreinecker S, Elbling L, Thallinger C, Pehamberger H, Micksche M, Berger W. Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. Melanoma Res. 2003;13:483–92.CrossRefPubMedGoogle Scholar
  71. 71.
    Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L. Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002;360:295–305.CrossRefPubMedGoogle Scholar
  72. 72.
    Paschen A, Méndez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer. 2003;103:759–67.CrossRefPubMedGoogle Scholar
  73. 73.
    Schiavo R, Tullio C, La Grotteria M, Andreotti IC, Scarpati B, Romiti L, Bozzi F, Pedrazzoli P, Siena S. Establishment and characterization of a new Ewing’s sarcoma cell line from a malignant pleural effusion. Anticancer Res. 2007;27:3273–8.PubMedGoogle Scholar
  74. 74.
    Nishio J, Iwasaki H, Ishiguro M, Ohjimi Y, Fujita C, Yanai F, Nibu K, Mitsudome A, Kaneko Y, Kikuchi M. Establishment and characterization of a novel human desmoplastic small round cell tumor cell line, JN-DSRCT-1. Lab Investig. 2002;82:1175–82.CrossRefPubMedGoogle Scholar
  75. 75.
    Kudo N, Ogose A, Hotta T, Kawashima H, Gu W, Umezu H, Toyama T, Endo N. Establishment of novel human dedifferentiated chondrosarcoma cell line with osteoblastic differentiation. Virchows Arch. 2007;451:691–9.CrossRefPubMedGoogle Scholar
  76. 76.
    Ikemoto S, Sugimura K, Yoshida N, Nakatani T. Chondrosarcoma of the urinary bladder and establishment of a human chondrosarcoma cell line (OCUU-6). Hum Cell. 2004;17:93–6.CrossRefPubMedGoogle Scholar
  77. 77.
    Sonobe H, Manabe Y, Furihata M, Iwata J, Oka T, Ohtsuki Y, Mizobuchi H, Yamamoto H, Kumano O, Abe S. Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II. Lab Investig. 1992;67:498–505.PubMedGoogle Scholar
  78. 78.
    Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127:2209–21.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Wang T, Wang L, Qian X, Yu L, Ding Y, Liu B. Relationship between gene expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in primary cancer cells isolated from malignant ascites. Cancer Investig. 2011;29:130–6.CrossRefGoogle Scholar
  80. 80.
    Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, Gardini G, Nizzoli R, Leonardi F, Gasparro D, Camisa R, Cavalli S, Silini EM, Ardizzoni A. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 2011;104:1372–6.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Wong DD, de Boer WB, Platten MA, Jo VY, Cibas ES, Kumarasinghe MP. HER2 testing in malignant effusions of metastatic gastric carcinoma: is it feasible? Diagn Cytopathol. 2015;43:80–5.CrossRefPubMedGoogle Scholar
  82. 82.
    Yoo KH, Kim NK, Kwon WI, Lee C, Kim SY, Jang J, Ahn J, Kang M, Jang H, Kim ST, Ahn S, Jang KT, Park YS, Park WY, Lee J, Heo JS, Park JO. Genomic alterations in biliary tract cancer using targeted sequencing. Transl Oncol. 2016;9:173–8.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Golan T, Atias D, Barshack I, Avivi C, Goldstein RS, Berger R. Ascites-derived pancreatic ductal adenocarcinoma primary cell cultures as a platform for personalised medicine. Br J Cancer. 2014;110:2269–76.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Lee JY, Kim SY, Park C, Kim NK, Jang J, Park K, Yi JH, Hong M, Ahn T, Rath O, Schueler J, Kim ST, Do IG, Lee S, Park SH, Ji YI, Kim D, Park JO, Park YS, Kang WK, Kim KM, Park WY, Lim HY, Lee J. Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget. 2015;6:25619–30.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Fushida S, Oyama K, Kinoshita J, Yagi Y, Okamoto K, Tajima H, Ninomiya I, Fujimura T, Ohta T. VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody. Onco Targets Ther. 2013;6:1445–51.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Ha SY, Lee J, Jang J, Hong JY, Do IG, Park SH, Park JO, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Kang WK, Kim KM. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. Int J Cancer. 2015;136:1629–35.CrossRefPubMedGoogle Scholar
  87. 87.
    Park S, Lee J, Do IG, Jang J, Rho K, Ahn S, Maruja L, Kim SJ, Kim KM, Mao M, Oh E, Kim YJ, Kim J, Choi YL. Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling. Sci Rep. 2014;4:3623.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Sakaizawa K, Ashida A, Uhara H, Okuyama R. Detection of BRAFV600K mutant tumor-derived DNA in the pleural effusion from a patient with metastatic melanoma. Clin Chem Lab Med. 2017;55:e92–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PathologyThe Norwegian Radium Hospital, Oslo University HospitalOsloNorway
  2. 2.Faculty of MedicineInstitute of Clinical Medicine, University of OsloOsloNorway

Personalised recommendations